Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Section 4 of 6

Clinical evidence

273 evidence topics · 40 sources

Study summaries

RAPIDe-3

Objective
Location and study date
Study design
Registry design details
FieldReported value
Other study ID number“PHA022121-C306”
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Masking“Quadruple”
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to onset of symptom relief by patient global impression of change as the primary endpoint
Key secondary endpoints: registry definitions
Outcome measureMeasure description
“Proportion of study drug-treated attacks achieving PGI-C rating of at least "a little better" at 4 hours post-treatment.”“The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
“Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment.”“The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
“Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S).”“Defined as achieving ≥1 point reduction in PGI-S (5-point scale) from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.”
“Time to complete symptom resolution, defined as achieving PGI-S rating of "none" within 48 hours post-treatment.”“The PGI-S (5-point scale) is used to evaluate the severity of HAE attack symptoms.”
“Time to End of Progression (EoP) in attack symptoms within 12 hours.”“EoP time defined as the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved.”
“Proportion of study drug-treated attacks requiring rescue medication within 24 hours post-treatment.”“Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.”
“Proportion of attacks achieving symptom resolution.”“Defined as achieving PGI-S rating of "none" with one dose of study drug at 24 hours post-treatment.”
“Time to substantial symptom relief by Angioedema Symptom Rating Scale (AMRA).”“Defined as a ≥50% reduction in AMRA composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.”
“Time to almost complete or complete symptom relief by AMRA.”“Defined as all item scores in AMRA having a value ≤10 for 2 consecutive timepoints within 24 hours post-treatment.”
“Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by AMRA.”“Defined as all item scores in AMRA having a value ≤10 at 24 hours post-treatment.”
“Time to EoP in attack symptoms within 12 hours.”“Defined as the earliest post-treatment timepoint after which every individual AMRA item is stable or improved at all subsequent timepoints.”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
All randomized participants: demographic and disease characteristics, 134 participants
CharacteristicAll randomized participants (N=134)
Age in years, mean (SD)“39.0 (14.7)”
Age ≥12 to <18 years, n (%)“10 (7.5)”
Age ≥18 to <65 years, n (%)“116 (86.6)”
Age ≥65 years, n (%)“8 (6.0)”
Female, n (%)“76 (56.7)”
BMI, mean (SD)“26.5 (5.9)”
White, n (%)“93 (69.4)”
Asian, n (%)“19 (14.2)”
Black or African American, n (%)“10 (7.5)”
Europe, n (%)“56 (41.8)”
Rest of world, n (%)“40 (29.9)”
North America, n (%)“38 (28.4)”
Years since HAE diagnosis, mean (SD)“17.7 (13.0)”
Attacks within 3 months before screening, mean (SD)“4.4 (3.3)”
HAE-C1INH type 1, n (%)“118 (88.1)”
HAE-C1INH type 2, n (%)“10 (7.5)”
Unspecified HAE-C1INH type 1 or 2, n (%)“2 (1.5)”
HAE-nC1INH, n (%)“4 (3.0)”
Current long-term prophylaxis use, n (%)“31 (23.1)”
Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants
CharacteristicDeucrictibant (n=101)Placebo (n=100)Overall (n=113)
Age, years, median (IQR)“36·0 (27·0–49·0)”“36·5 (28·0–50·0)”“36·0 (27·0–50·0)”
Male“46 (46%)”“46 (46%)”“51 (45%)”
Female“55 (54%)”“54 (54%)”“62 (55%)”
White“70 (69%)”“70 (70%)”“80 (71%)”
Asian“17 (17%)”“16 (16%)”“17 (15%)”
Black or African American“4 (4%)”“6 (6%)”“6 (5%)”
North America“21 (21%)”“26 (26%)”“28 (25%)”
Europe“47 (47%)”“41 (41%)”“50 (44%)”
Rest of world“33 (33%)”“33 (33%)”“35 (31%)”
BMI, kg/m2, median (IQR)“25·2 (22·3–28·2)”“25·6 (22·5–29·2)”“25·5 (22·4–28·9)”
HAE-C1INH-type 1“90 (89%)”“91 (91%)”“102 (90%)”
HAE-C1INH-type 2“8 (8%)”“8 (8%)”“8 (7%)”
HAE-nC1INH“2 (2%)”“0”“2 (2%)”
Unspecified HAE-C1INH type 1 or 2“1 (1%)”“1 (1%)”“1 (1%)”
Time since diagnosis, years, median (IQR)“15·0 (7·0–24·0)”“15·5 (7·0–24·5)”“15·0 (7·0–24·0)”
Concomitant long-term prophylaxis: yes“20 (20%)”“24 (24%)”“26 (23%)”
Long-term prophylaxis: lanadelumab“8 (8%)”“10 (10%)”“11 (10%)”
Long-term prophylaxis: berotralstat“5 (5%)”“7 (7%)”“7 (6%)”
Long-term prophylaxis: C1-esterase inhibitor“4 (4%)”“5 (5%)”“5 (4%)”
Long-term prophylaxis: danazol“3 (3%)”“2 (2%)”“3 (3%)”
Attacks in the 3 months before screening: 2–5“72 (71%)”“71 (71%)”“83 (73%)”
Attacks in the 3 months before screening: 6–10“19 (19%)”“19 (19%)”“20 (18%)”
Attacks in the 3 months before screening: 11–15“6 (6%)”“6 (6%)”“6 (5%)”
Attacks in the 3 months before screening: 16–20“2 (2%)”“2 (2%)”“2 (2%)”
Primary efficacy analysis set: demographic and disease characteristics, 88 participants
CharacteristicPrimary efficacy analysis group (N=88)
Age in years, mean (SD)“38.7 (13.6)”
Age ≥12 to <18 years, n (%)“5 (5.7)”
Age ≥18 to <65 years, n (%)“80 (90.9)”
Age ≥65 years, n (%)“3 (3.4)”
Female, n (%)“47 (53.4)”
North America, n (%)“19 (21.6)”
Europe, n (%)“38 (43.2)”
Rest of world, n (%)“31 (35.2)”
Years since HAE diagnosis, mean (SD)“17.3 (12.24)”
HAE-C1INH type 1, n (%)“79 (89.8)”
HAE-C1INH type 2, n (%)“8 (9.1)”
Unspecified HAE-C1INH type 1 or 2, n (%)“1 (1.1)”
Current long-term prophylaxis use, n (%)“18 (20.5)”
Efficacy results
Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks
Endpoint and statisticDeucrictibant N'Deucrictibant resultPlacebo N'Placebo resultp value
Primary: time to onset of symptom relief (PGI-C), median time (95% CI), h“83/88”“1·28 (1·05 to 1·52)”“87/88”“>12 (5·82 to >12)”“<0·0001”
Attacks meeting onset of symptom relief at 4 hours (PGI-C), n (%)“83/88”“69/83 (83%)”“87/88”“24/87 (28%)”“<0·0001”
Time to substantial symptom relief (PGI-C), median time (95% CI), h“83/88”“2·85 (2·08 to 3·35)”“87/88”“>12 (10·30 to >12)”“<0·0001”
Time to reduction in attack severity (PGI-S), median time (95% CI), h“83/88”“2·41 (1·70 to 2·98)”“84/88”“>12 (12·34 to >12)”“<0·0001”
Time to complete symptom resolution (PGI-S), median time (95% CI), h“83/88”“11·95 (8·61 to 21·79)”“87/88”“>48 (>48 to >48)”“<0·0001”
Time to end of progression (PGI-C), median time (95% CI), min“83/88”“17·47 (16·27 to 19·17)”“87/88”“228·67 (61·82 to 599·60)”“<0·0001”
Complete symptom resolution with one dose at 24 hours (PGI-S), n (%)“83/88”“50/83 (60%)”“87/88”“13/88 (15%)”“<0·0001”
Regional subgroups, North America and Europe or rest of world: all participants with treated attacks
Region and endpointDeucrictibantPlacebo
North America: time to onset of symptom relief, median“1.20 hours (95% CI: 0.84, 1.84)”“6.55 hours (95% CI: 1.88, >12)”
Europe/Rest of World: time to onset of symptom relief, median“1.28 hours (95% CI: 1.04, 1.41)”“>12 hours (95% CI: 5.74, >12)”
North America: time to reduction in attack severity, median“2.43 hours (95% CI: 1.03, 5.12)”“>12 hours (95% CI: 2.65, >12)”
Europe/Rest of World: time to reduction in attack severity, median“2.53 hours (95% CI: 1.70, 2.98)”“>12 hours (95% CI: 12.10, >12)”
North America: time to complete symptom resolution, median“11.61 hours (95% CI: 2.94, 26.14)”“>48 hours (95% CI: 17.21, >48)”
Europe/Rest of World: time to complete symptom resolution, median“12.04 hours (95% CI: 8.64, 21.79)”“>48 hours (95% CI: >48, >48)”
North America: onset of symptom relief at 4 hours“77.8% (n=14/18)”“46.2% (n=12/26)”
Europe/Rest of World: onset of symptom relief at 4 hours“84.6% (n=66/78)”“26.4% (n=19/72)”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events, safety analysis set
Event categoryNon-attack deucrictibant (n=10): participants, n (%)Non-attack: events, nTreated attack deucrictibant (n=100): participants, n (%)Deucrictibant: events, nTreated attack placebo (n=101): participants, n (%)Placebo: events, n
Any treatment-emergent adverse event“3 (30%)”“4”“24 (24%)”“40”“17 (17%)”“22”
Any treatment-emergent adverse event related to study drug“0”“0”“5 (5%)”“6”“1 (1%)”“1”
Any serious treatment-emergent adverse event“0”“0”“1 (1%)”“1”“1 (1%)”“1”
Any serious treatment-emergent adverse event related to study drug“0”“0”“0”“0”“0”“0”
Any severe treatment-emergent adverse event“0”“0”“1 (1%)”“2”“1 (1%)”“3”
Any severe treatment-emergent adverse event related to study drug“0”“0”“0”“0”“0”“0”
Any treatment-emergent adverse event within 3 days post-treatment“0”“0”“15 (15%)”“17”“2 (2%)”“3”
Treatment-emergent adverse event within 3 days related to study drug“0”“0”“5 (5%)”“6”“1 (1%)”“1”
Any serious treatment-emergent adverse event within 3 days post-treatment“0”“0”“0”“0”“0”“0”
Any severe treatment-emergent adverse event within 3 days post-treatment“0”“0”“0”“0”“0”“0”
Treatment-emergent adverse event leading to trial or study drug discontinuation“0”“0”“0”“0”“0”“0”
Treatment-emergent adverse event leading to death“0”“0”“0”“0”“0”“0”
Fatigue within 3 days post-treatment“0”“0”“2 (2%)”“2”“0”“0”
Maximum severity grade of treatment-emergent adverse events, safety analysis set
Participants with ≥1 TEAE by maximum gradePlacebo (N=101)Deucrictibant (N=100)
Any TEAEs“17 (16.8)”“24 (24.0)”
Maximum Grade 1 (Mild)“10 (9.9)”“13 (13.0)”
Maximum Grade 2 (Moderate)“6 (5.9)”“10 (10.0)”
Maximum Grade 3 (Severe)“0”“1 (1.0)”
Maximum Grade 4 (Life-threatening)“1 (1.0)”“0”
Maximum Grade 5 (Fatal)“0”“0”
Study limitations
Summary
  • The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
  • Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
  • The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
  • Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
  • Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
  • Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
  • Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
  • Health-related quality of life outcomes were exploratory endpoints planned for separate publication.

RAPIDe-1

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in the 3-Symptom composite visual analogue scale score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Registry participant flow by randomized dose cohort, Part I and Part II
MilestoneDeucrictibant 10 mg cohortDeucrictibant 20 mg cohortDeucrictibant 30 mg cohort
Part I started“24”“25”“25”
Part I completed“24”“24”“25”
Part I withdrawal by subject“0”“1”“0”
Part II started“24”“24”“25”
Part II completed“16”“12”“12”
Part II not completed“8”“12”“13”
Part II withdrawal by subject“2”“3”“5”
Part II not completed: “Participants Met Primary Analysis Criteria”“6”“9”“8”
Baseline characteristics
Demographics and HAE characteristics by dose cohort, full analysis set
CharacteristicDeucrictibant 10 mg (n=24)Deucrictibant 20 mg (n=25)Deucrictibant 30 mg (n=25)
Age, years, median (IQR)“44 (31–53)”“45 (36–57)”“39 (25–53)”
Female, n (%)“17 (71%)”“17 (68%)”“15 (60%)”
White, n (%)“22 (92%)”“24 (96%)”“25 (100%)”
HAE-C1INH type 1, n (%)“19 (79%)”“22 (88%)”“24 (96%)”
HAE-C1INH type 2, n (%)“5 (21%)”“2 (8%)”“1 (4%)”
Time since diagnosis, years, median (IQR)“18 (10–26)”“21 (13–37)”“23 (10–37)”
More than 4 attacks in the 4 months before screening, n (%)“20 (83%)”“20 (80%)”“20 (80%)”
Long-term prophylactic treatment history, n (%)“3 (13%)”“5 (20%)”“5 (20%)”
Registry baseline age and ethnicity, full analysis set
CharacteristicDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgTotal
Participants“24”“25”“25”“74”
Age, years, mean (SD)“42.9”( “14.15”)“45.7”( “13.89”)“41.4”( “15.38”)“43.3”( “14.41”)
Aged 65 to 84 years“2”“1”“2”“5”
Hispanic or Latino“3”“2”“0”“5”
Efficacy results
Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants
MeasureDeucrictibant 10 mg (n=21)Deucrictibant 20 mg (n=16)Deucrictibant 30 mg (n=20)Placebo (n=51)
Attacks with VAS-3 at 4 h“33”“27”“30”“43”
VAS-3 at 4 h, mean (SD)“12·09 (14·47)”“11·93 (9·97)”“14·71 (10·51)”“30·09 (18·20)”
LSM difference vs placebo (95% CI)“−16·75 (−21·52 to −11·97)”“−15·02 (−20·22 to −9·81)”“−16·28 (−21·27 to −11·29)”Not applicable
p valueNot reported“<0·0001”“<0·0001”Not applicable
Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data
GroupParticipantsLS mean change in VAS-3 (SE)LS mean difference vs placebo (95% CI)p value
Deucrictibant 10 mg“21”“-14.83”( “1.833”)“-16.75”( “-21.52”to “-11.97”)“< 0.0001”, “Nominal p-value”
Deucrictibant 20 mg“16”“-13.10”( “2.111”)“-15.02”( “-20.22”to “-9.81”)“< 0.0001”
Deucrictibant 30 mg“20”“-14.37”( “1.975”)“-16.28”( “-21.27”to “-11.29”)“< 0.0001”
Placebo“51”“1.92”( “1.596”)Not applicableNot applicable
Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Endpoint and measureDeucrictibant 10 mg (37 attacks)Deucrictibant 20 mg (28 attacks)Deucrictibant 30 mg (31 attacks)Placebo (51 attacks)
Onset of symptom relief (≥30% VAS-3 reduction), median h (95% CI)“2·1 (1·5 to 2·9)”“2·7 (1·9 to 3·5)”“2·5 (1·9 to 3·8)”“8·0 (7·6 to NE)”
Onset of symptom relief, hazard ratio (95% CI)“3·81 (2·01 to 7·20)”“3·08 (1·50 to 6·30)”“3·61 (2·10 to 6·19)”Not applicable
Onset of symptom relief, p valueNot reported“0·0021”“<0·0001”Not applicable
≥50% VAS-3 reduction, median h (95% CI)“3·3 (2·4 to 3·9)”“4·0 (2·9 to 6·0)”“4·0 (3·3 to 5·8)”“22·8 (20·0 to 24·1)”
≥50% VAS-3 reduction, hazard ratio (95% CI)“4·55 (2·41 to 8·59)”“3·65 (1·80 to 7·38)”“3·87 (2·26 to 6·63)”Not applicable
≥50% VAS-3 reduction, p valueNot reported“0·0003”“<0·0001”Not applicable
Almost complete or complete symptom relief, median h (95% CI)“5·8 (3·6 to 7·5)”“20·0 (4·5 to 20·0)”“20·0 (6·0 to 20·1)”“42·0 (22·0 to NE)”
Almost complete or complete symptom relief, hazard ratio (95% CI)“5·09 (2·81 to 9·22)”“2·25 (1·19 to 4·27)”“2·65 (1·61 to 4·38)”Not applicable
Almost complete or complete symptom relief, p valueNot reported“0·013”“<0·0001”Not applicable
Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Endpoint and measureDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgPlacebo
MSCS, attacks“32”“26”“27”“40”
MSCS, mean change from pre-treatment (SD)“−1·08 (0·13)”“−0·91 (0·14)”“−0·68 (0·14)”“−0·29 (0·11)”
MSCS, LSM difference vs placebo (95% CI)“−0·79 (−1·11 to −0·46)”“−0·61 (−0·97 to −0·26)”“−0·39 (−0·73 to −0·04)”Not applicable
MSCS, p valueNot reported“0·0008”“0·029”Not applicable
TOS, attacks“32”“25”“28”“40”
TOS, mean (SD) score“57·03 (58·63)”“62·67 (36·09)”“68·75 (38·86)”“−2·71 (62·49)”
TOS, LSM difference vs placebo (95% CI)“64·13 (40·35 to 87·91)”“62·69 (36·71 to 88·67)”“71·06 (46·09 to 96·03)”Not applicable
TOS, p valueNot reported“<0·0001”“<0·0001”Not applicable
Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Window and measureDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgPlacebo
Within 12 h, attacks with rescue medication, n (%)“7 (19%)”“3 (11%)”“2 (7%)”“31 (61%)”
Within 12 h, OR vs placebo (95% CI)“0·15 (0·06 to 0·37)”“0·08 (0·02 to 0·35)”“0·04 (0·01 to 0·18)”Not applicable
Within 24 h, attacks with rescue medication, n (%)“9 (24%)”“3 (11%)”“4 (13%)”“37 (73%)”
Within 24 h, OR vs placebo (95% CI)“0·12 (0·05 to 0·29)”“0·05 (0·01 to 0·19)”“0·06 (0·02 to 0·18)”Not applicable
Within 48 h, attacks with rescue medication, n (%)“9 (24%)”“4 (14%)”“5 (16%)”“37 (73%)”
Within 48 h, OR vs placebo (95% CI)“0·12 (0·05 to 0·29)”“0·07 (0·02 to 0·24)”“0·07 (0·02 to 0·22)”Not applicable
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events within 5 days by part and dose, safety analysis set
EventPart 1, 10 mg (n=23)Part 1, 20 mg (n=24)Part 1, 30 mg (n=25)Part 2, 10 mg (38 attacks; n'=21)Part 2, 20 mg (29 attacks; n'=16)Part 2, 30 mg (36 attacks; n'=22)Part 2, placebo (53 attacks; n'=53)
Any treatment-emergent adverse event“2 (9%)”“2 (8%)”“4 (16%)”“3 (8%)”, “3 (14%)”“1 (3%)”, “1 (6%)”“2 (6%)”, “2 (9%)”“3 (6%)”, “3 (6%)”
Any treatment-related treatment-emergent adverse event“1 (4%)”“1 (4%)”“0”“0”“0”“1 (3%)”, “1 (5%)”“1 (2%)”, “1 (2%)”
Registry adverse event counts by part and treatment group
Event groupDeathsSerious adverse eventsOther adverse events
Part I, 10 mg (participants)“0”of “23”“0”of “23”“2”of “23”
Part I, 20 mg (participants)“0”of “24”“0”of “24”“2”of “24”
Part I, 30 mg (participants)“0”of “25”“0”of “25”“4”of “25”
Part II, 10 mg (study drug treated attacks)“0”of “38”“0”of “38”“3”of “38”
Part II, 20 mg (study drug treated attacks)“0”of “29”“0”of “29”“1”of “29”
Part II, 30 mg (study drug treated attacks)“0”of “36”“0”of “36”“2”of “36”
“Part II Placebo”“0”of “53”“0”of “53”“4”of “53”
Treatment-related adverse events in the top-line data and a congress poster
Study limitations
Summary
  • The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
  • Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
  • The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
  • The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
  • The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
  • TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.

RAPIDe-2

Objective
Location and study date
Registry dates, status, and number of locations
FieldReported value
Recruitment status“Enrolling by invitation”
Study start (actual)“2022-12-28”
Primary completion (estimated)“2027-06”
Study completion (estimated)“2027-06”
First posted“2022-05-31”
Last update posted“2026-07-21”
Locations“This study has 60 locations”
Study design
Registry design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Part A participants, combined dose group (N=19)
CharacteristicDeucrictibant IR capsule, combined dose group
Age in years, mean (SD)“44.4 (17.6)”
Sex: male / female, n (%)“7 (36.8) / 12 (63.2)”
Race: White / other, n“18 / 1”
BMI, mean (SD)“26.8 (4.0)”
Years since HAE diagnosis, mean (SD)“23.3 (15.2)”
HAE-1, n (%)“17 (89.5)”
HAE-2, n (%)“2 (10.5)”
Participants with and without upper airway attacks
CharacteristicWith ≥1 upper airway attack (n=7)Without upper airway attacks (n=12)
Age in years, mean (SD)“46.0 (19.5)”“43.4 (17.2)”
Sex: male / female, n (%)“4 (57) / 3 (43)”“3 (25) / 9 (75)”
Race: White / other, n“7 / 0”“11 / 1”
BMI, mean (SD)“27.1 (3.8)”“26.7 (4.2)”
Years since HAE diagnosis, mean (SD)“20.8 (18.9)”“24.7 (13.3)”
HAE-1, n (%)“6 (85.7)”“11 (91.7)”
HAE-2, n (%)“1 (14.3)”“1 (8.3)”
Efficacy results
Median time to key efficacy endpoints, Part A (465 attacks)
EndpointMedian time95% CI
Onset of symptom relief (PGI-C)“1.1 hours”“(1.0, 1.1)”
Substantial symptom relief (PGI-C)“2.5 hours”“(2.1, 2.9)”
Reduction in attack severity (PGI-S)“2.8 hours”“(2.3, 2.9)”
Complete attack resolution (PGI-S)“10.6 hours”“(8.5, 11.5)”
Proportion of attacks achieving key endpoints, evaluable attacks (457 PGI-C, 449 PGI-S)
EndpointProportion of attacksAttacks
Onset of symptom relief by 12 hours“97.8%”“447/457”
Substantial symptom relief by 12 hours“95.2%”“435/457”
Reduction in attack severity by 12 hours“96.7%”“434/449”
Complete symptom resolution at 24 hours“86.9%”“390/449”
Attacks treated with a single dose and rescue medication use, evaluable attacks (457)
AttacksOne doseTwo doses
Overall“86.2%”“394/457”“13.8%”“63/457”
Complete attack resolution within 24 hours“89.2%”“348/390”“10.8%”“42/390”
Upper airway attacks compared with non-upper airway attacks, post hoc analysis
EndpointUpper airway attacks (n=7 participants)Non-upper airway attacks in participants with upper airway attacks (n=7)All non-upper airway attacks (n=19)
Total number of attacks treated“14”“177”“451”
Time to onset of symptom relief, median hours (95% CI)“1.4 (0.8–3.0)”“1.0 (1.0–1.2)”“1.1 (1.0–1.1)”
Time to substantial symptom relief, median hours (95% CI)“3.6 (2.0–6.1)”“2.7 (2.1–3.0)”“2.4 (2.1–2.8)”
Time to reduction in attack severity, median hours (95% CI)“1.8 (0.9–3.0)”“2.1 (2.0–2.8)”“2.8 (2.4–2.9)”
Time to complete attack resolution, median hours (95% CI)“8.9 (3.9–36.3)”“8.0 (7.3–10.7)”“10.6 (8.5–11.5)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events within 3 days of study drug, Part A (N=19; 465 attacks)
Adverse eventsDeucrictibant IR capsule, combined dose group
Attacks with any TEAE, n (%)“12 (2.6)”
Treatment-related TEAEs, n“0”
Serious TEAEs, n“1”
Treatment-related serious TEAEs, n“0”
TEAEs leading to study drug discontinuation, study withdrawal, or death, n“0”
Study limitations
Summary
  • RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
  • Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
  • Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
  • Upper airway results rest on 14 attacks in seven participants.
  • Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
  • Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.

PHA121-C001

Objective
Location and study date
Study design
Cohorts: pharmacokinetic part 1 and pharmacodynamic part 2
CohortParticipants
Part 1 (PK), 1 mg, fasted“N=6”
Part 1 (PK), 2 mg, fasted“N=6”
Part 1 (PK), 4.5 mg, fasted“N=6”
Part 1 (PK), 12 mg, fasted“N=6”
Part 1 (PK), 22 mg, fasted“N=6”
Part 1 (PK), 22 mg, after high-calorie, high-fat breakfast“N=6”
Part 1 (PK), placebo“N=12”
Part 2 (PD), 12 mg, fasted“N=8”
Part 2 (PD), 22 mg, fasted“N=8”
Part 2 (PD), placebo“N=4”
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Pharmacokinetic parameters by dose (N=6 per dose)
Bradykinin challenge: modeled duration of effect compared with icatibant 30 mg
ResponseIcatibant 30 mg (s.c.)PHA121 12 mg (oral)PHA121 22 mg (oral)
Diastolic blood pressure, time (h) above EC50 at a 75% confidence level“6”“11.5”“14”
Mean arterial blood pressure, time (h) above EC50 at a 75% confidence level“6”“12”“15.5”
Heart rate, time (h) above EC50 at a 75% confidence level“6.5”“10”“13”
Diastolic blood pressure, time (h) above EC85 at a 50% confidence level“5.5”“7.5”“10”
Mean arterial blood pressure, time (h) above EC85 at a 50% confidence level“5.5”“7”“10”
Heart rate, time (h) above EC85 at a 50% confidence level“5.5”“6.5”“9.5”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by dose group
Dose groupParticipantsAny AE, n (%)Any related AEAny severe AEAny serious AE
1 mg, fasted“N=6”“2 (33.3%)”“0”“0”“0”
2 mg, fasted“N=6”“1 (16.7%)”“0”“0”“0”
4.5 mg, fasted“N=6”“1 (16.7%)”“0”“0”“0”
12 mg, fasted“N=14”“5 (35.7%)”“2 (14.3%)”“0”“0”
22 mg, fasted“N=14”“2 (14.3%)”“1 (7.1%)”“0”“0”
22 mg after HCHF breakfast“N=6”“1 (16.7%)”“0”“0”“0”
Placebo“N=16”“5 (31.3%)”“1 (6.3%)”“0”“0”
Study limitations
Summary
  • PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
  • Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
  • The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
  • Safety was followed for 72 hours after a single dose.
  • The results are reported in two posters described in a company press release and in the company's registration statement.